Boston Scientific Corporation (BSX)
Boston Scientific Corporation (BSX) M&A Call Transcript
Boston Scientific Corporation (BSX) M&A Call Transcript
BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies
Boston Scientific stock may rebound after agreeing to buy Valencia Technologies, adding the FDA-approved eCoin ITNS device to expand its Urology portfolio.
Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Boston Scientific (BSX) reached $95.72 at the closing of the latest trading day, reflecting a -1.97% change compared to its last close.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition remain risks.
Boston Scientific (BSX) Just Overtook the 50-Day Moving Average
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
Boston Scientific (BSX) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Boston Scientific (BSX) settling at $97.79, representing a +2.42% change from its previous close.
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Boston Scientific: Premium MedTech Growth Story With Attractive Valuation Upside
Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution in Cardiovascular and MedSurg segments, and sustained double-digit revenue and EPS expansion. Recent Q3 results exceeded expectations, prompting management to raise FY25 guidance; high demand for Watchman and FARAPULSE are key growth drivers.
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
Should You Hold On To BSX Stock Despite Its Premium Valuation?
Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks.
